NEW YORK (GenomeWeb News) – Zygem will market Rubicon Genomics' PicoPlex single-cell amplification kits in Australia and New Zealand, under a non-exclusive agreement, Rubicon said today.
Rubicon's kits are used to amplify small clinical samples into large amounts of pure DNA, and they are licensed and sold to clinical markets for pre-implantation and prenatal testing, cancer testing, and for making diagnostics.
DNA amplified using the PicoPlex can be analyzed using qPCR, microarrays, and next-generation sequencing technologies for either research or diagnostic purposes, and it represents genomic sequencings without the common problem of allele dropouts, Ann Arbor, Mich.-based Rubicon said.
Zygem makes DNA and RNA extraction and detection products and enzymes used in molecular biology and diagnostic applications. Its customers include those involved in basic research, forensics, clinical diagnostics, and agriculture.
"The PicoPlex technology nicely complements Zygem's advanced DNA extraction products and we are looking forward to bringing this cutting-edge technology to the markets we serve in Australia and New Zealand," Paul Kinnon, CEO of Zygem, said in a statement.